Riskpilot← Back to searchSign inGet full accessVIPERGEN ApS
APSActiveCVR 28851758Gammel Kongevej 23A, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 200516 employees
Revenue 2024
DKK 12,3M
-35% vs 2023
EBITDA margin
2.5%
-95% vs 2023
Equity ratio
20.9%
Financial strength
Net profit 2024
DKK -318K
-106% vs 2023
| Revenue | DKK 12,3M | -35% |
| EBITDA | DKK 307K | -95% |
| Net profit | DKK -318K | -106% |
| Total assets | DKK 31,7M | +80% |
| Equity | DKK 6,6M | -5% |
| Employees | 16 | — |
Legal name
VIPERGEN ApS
CVR number
28851758
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22. juni 2005
Share capital
DKK 218.575
Employees
16 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet repræsenteres i alle forhold af direktøren, som kan tegne Selskabet. Selskabet kan endvidere tegnes af bestyrelsesformanden eller af to af bestyrelsens medlemmer eller den samlede bestyrelse i forening
Company purpose
Selskabets formål er direkte eller indirekte at drive virksomhed med forskning og udvikling, og hvad der relaterer sig hertil. Selskabet indgår som komplementar VIPERGEN Pharmaceuticals K/S.
Address
Gammel Kongevej 23A, 1.
Phone
+4525236680
Email
nha@vipergen.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 4.345 | 9.980 | 5.644 | 9.158 | 3.443 | 3.128 | 19.959 | 12.659 | 19.053 | 12.305 |
| Staff expenses | -0 | -0 | -0 | -6.378 | -5.337 | -6.869 | -7.689 | -9.384 | -8.771 | -10.671 | -11.694 | -12.260 | -11.998 |
| EBITDA | -10 | -13 | -10 | -2.033 | 4.643 | -1.225 | 1.469 | -5.941 | -5.643 | 9.289 | 964 | 6.793 | 307 |
| Depreciation & amort. | -25 | -25 | -25 | -18 | -53 | -64 | -218 | -417 | -471 | -406 | -522 | -551 | -574 |
| EBIT | -35 | -38 | -35 | -2.052 | 4.590 | -1.289 | 1.252 | -6.358 | -6.114 | 8.882 | 442 | 6.242 | -267 |
| Net financials | 44 | 44 | 47 | -3 | -65 | -52 | 3 | -70 | -241 | -443 | -224 | -210 | -376 |
| Profit before tax | 9 | 6 | 12 | -2.054 | 4.525 | -1.341 | 1.255 | -6.428 | -6.355 | 8.439 | 219 | 6.031 | -643 |
| Tax | 5 | 1 | 9 | 2 | 545 | -276 | 300 | -1.428 | -7 | -27 | -835 | 1.127 | -325 |
| Net profit | 4 | 4 | 3 | -2.056 | 3.981 | -1.064 | 955 | -5.000 | -6.348 | 8.466 | 1.054 | 4.904 | -318 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.092 | 2.002 | 2.051 | 3.659 | 10.220 | 8.839 | 8.949 | 5.343 | 5.755 | 13.714 | 8.607 | 17.540 | 31.653 |
| Equity | 1.943 | 1.948 | 1.951 | -106 | 3.875 | 2.918 | 3.873 | -1.128 | -7.476 | 990 | 2.044 | 6.948 | 6.630 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 311 | 827 | 827 | 0 | 0 | 0 |
| Short-term debt | 149 | 54 | 100 | 3.764 | 6.345 | 5.922 | 5.053 | 6.136 | 12.386 | 11.896 | 6.563 | 9.229 | 21.928 |
| Total debt | 149 | 54 | 100 | 3.764 | 6.345 | 5.922 | 5.053 | 6.447 | 13.213 | 12.724 | 6.563 | 9.229 | 21.928 |
EBITDA margin
2.5%
This company
15.8%
Market median
-84% vs market
20122024
Equity ratio
20.9%
This company
38.2%
Market median
-45% vs market
20122024
Return on equity
-4.8%
This company
18.4%
Market median
-126% vs market
20122024
Net profit margin
-2.6%
This company
8.1%
Market median
-132% vs market
20122024
Asset turnover
0.39×
This company
1.12×
Market median
-65% vs market
20122024
Debt / equity
3.77×
This company
0.62×
Market median
-508% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2005 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50.0% | 50.0% | 2014 | |
| Individual | 33.3% | 33.3% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VIPERGEN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eigil Bjerl Nielsen | Chairman | 0 companies |